Table 4. Factors Associated With PCI Use Within Three Months Among Newly Diagnose AMI patients.
| Year Adjusted* | + Patient Characteristics | + County Random Effects | FE Logit Model | |||||
| Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | |||||
| Black | −0.019c | (−0.028–−0.010) | 0.002 | (−0.010–0.014) | −0.011a | (−0.023–0.001) | 0 | (−0.017–0.016) |
| Male | 0.003a | (−0.000–0.007) | 0.004b | (0.001–0.007) | 0.002 | (−0.001–0.005) | ||
| Age 65–74 | −0.027c | (−0.034–−0.020) | −0.029c | (−0.034–−0.023) | −0.029 | (−0.035–−0.023) | ||
| Age 75+ | −0.115c | (−0.124–−0.106) | −0.116c | (−0.122–−0.111) | −0.115c | (−0.122–−0.108) | ||
| Primary payer: Medicare managed care | 0.007 | (−0.011–0.025) | 0.009c | (0.005–0.014) | 0.008c | (−0.003–0.018) | ||
| Second payer: Medicaid | −0.030c | (−0.044–−0.016) | −0.024c | (−0.030–−0.017) | −0.023c | (−0.035–−0.011) | ||
| Second payer: private insurance | 0.004 | (−0.012–0.020) | 0.011c | (0.007–0.014) | 0.011c | (0–0.022) | ||
| Log household income (zip code level) | 0.032c | (0.011–0.053) | 0.013c | (0.006–0.020) | 0.011c | (0.003–0.018) | ||
| Transferred admission | 0.069c | (0.052–0.085) | 0.073c | (0.067–0.079) | 0.057c | (0.044–0.07) | ||
| Emergency admission | −0.046c | (−0.063–−0.029) | −0.051c | (−0.055–−0.046) | −0.052c | (−0.063–−0.04) | ||
| Hypertension | 0.056c | (0.051–0.061) | 0.055c | (0.052–0.059) | 0.057c | (0.053–0.061) | ||
| Congestive heart failure | −0.063c | (−0.076–−0.051) | −0.067c | (−0.086–−0.047) | −0.107 | (−0.125–−0.09) | ||
| Diabetes | −0.001 | (−0.005–0.003) | 0.000 | (−0.004–0.004) | 0.002 | (−0.002–0.007) | ||
| Renal failure | −0.058c | (−0.064–−0.051) | −0.061c | (−0.067–−0.054) | −0.054c | (−0.061–−0.048) | ||
| Cancer | −0.018c | (−0.026–−0.011) | −0.017c | (−0.026–−0.007) | −0.023c | (−0.032–−0.014) | ||
| Cardiogenic shock | −0.040c | (−0.053–−0.028) | −0.044c | (−0.051–−0.037) | −0.043c | (−0.055–−0.03) | ||
| Other coronary artery diseases | 0.103c | (0.093–0.113) | 0.097c | (0.094–0.101) | 0.104c | (0.097–0.111) | ||
| Prior CABG | −0.029c | (−0.037–−0.020) | −0.030c | (−0.038–−0.021) | −0.022c | (−0.029–−0.016) | ||
| Prior PTCA | 0.065c | (0.052–0.077) | 0.059c | (0.052–0.066) | 0.047c | (0.039–0.056) | ||
| Elixhauser 1 | −0.051c | (−0.057–−0.045) | −0.052c | (−0.057–−0.048) | −0.065c | (−0.07–−0.06) | ||
| Elixhauser 2 | −0.085c | (−0.093–−0.077) | −0.087c | (−0.092–−0.082) | −0.098c | (−0.104–−0.092) | ||
| Elixhauser 3+ | −0.115c | (−0.125–−0.105) | −0.117c | (−0.123–−0.110) | −0.124c | (−0.131–−0.117) | ||
| White, mean PTCA use rate | 0.157 | (0.145–0.168) | 0.156 | (0.146–0.166) | 0.140 | (0.131–0.150) | 0.156 | (0.155–0.157) |
*
Standard errors in all models are adjusted for correlation in patients living in the same county.
a
p<0.1;
b
p<0.05;
c
p<0.01 (two-tailed tests).